Table 1.

Clinical outcomes of different clinicopathological features guided RAT.

Study	Study design	Number	Clinical-pathological features	Follow-up period	Outcome	Prognosis improved	Dosage	Benefited groups	P
Ruel(2015) (12)	Retrospective	21870	Intermediate risk patients, as defined by ATA risk and AJCC disease stage T3, N0, M0 or Mx and T1–3, N1, M0 or Mx.	6y	OS	Yes	Na	Intermediate risk patients, as defined by ATA risk and AJCC disease stage T3, N0, M0 or Mx and T1–3, N1, M0 or Mx.	<0.001
Al-Qahtani(2015) (13)	Retrospective	326	PTMC with aggressive histopathologic variants, multifocality, extrathyro idal extension, lymphovascular space invasion, tumor size (>0.5 cm) and lymph node involvement	median 8.05y(1.62-11.4y)	DFS	Yes	30-200mCi; 100mCi is recommended for N0	PTMC with aggressive histopathologic variants, multifocality, lymphovascular space invasion, lymphovascular space invasion, tumor size (>0.5 cm) and lymph node involvement	<0.05
Creach(2012) (14)	Retrospective	407	Size of PTMC, histological subtype, positive lymph nodes on first WBS, PTMC (≤0.8 cm), lymph node metastases, pathology, vascular invasion, capsular invasion, soft tissue invasion, or positive surgical margins.	Median 5.3y(0.2-51 y)	5-y RFS	Yes	Median 100mCi	PTMC (≤0.8 cm), lymph node metastases.	<0.05
Kim(2013) (15)	Retrospective	480	Patients with PTMC with microscopic extrathyroidal extension, cervical lymph node metastases or multifocality (Intermediate-risk)	median 5.3y(0.08-15.4y)	DFS	No	Cumulative 30-300mCi	Patients with PTMC with microscopic extrathyroidal extension, cervical lymph node metastases or multifocality (Intermediate-risk)	0.79
Ballal(2016) (16)	Retrospective	254	Patients with T1-3 tumor, N1a/1b and with no distant metastasis (M0).	10.3y	DFS	No	30-100mCi	Patients with T1-3 tumor, N1a/1b and with no distant metastasis (M0).	0.005

Here, current studies with long-term follow-up and large sample sizes are listed.